Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 8—August 2016
Research

Outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi Infections after Prostate Biopsies, France, 2014

Skerdi HaviariComments to Author , Pierre Cassier, Cédric Dananché, Monique Hulin, Olivier Dauwalder, Olivier Rouvière, Xavier Bertrand, Michel Perraud, Thomas Bénet, and Philippe Vanhems
Author affiliations: Hospices Civils de Lyon, Lyon, France (S. Haviari, P. Cassier, C. Dananché, M. Hulin, O. Dauwalder, O. Rouvière, M. Perraud, T. Bénet, P. Vanhems); Université Claude Bernard, Lyon (S. Haviari, P. Cassier, C. Dananché, O. Dauwalder, O. Rouvière, M. Perraud, T. Bénet, P. Vanhems); Centre International de Recherche en Infectiologie, Lyon (P. Cassier, O. Dauwalder, T. Bénet, P. Vanhems); Centre Hospitalier Régional Universitaire de Besançon, Besançon, France (X. Bertrand); Laboratoire des Pathogènes Émergents–Fondation Mérieux, Lyon (T. Bénet, P. Vanhems)

Main Article

Table 3

Clinical and microbiologic history of retrospective surveillance patients in the study of an outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi infections occurring after prostate biopsies, France*

Characteristic Patient ID
A B C D E F
Date of biopsy 2011 Nov 23 2011 Dec 16 2012 May 7 2012 May 31 2012 July 9 2012 Nov 30
Patient age at onset, y 57 79 75 65 76 68
Days between biopsy and urinalysis 5 1 8 3 9 2
Highest fever, °C 40 39 None 39 38.4 None
Localized symptoms Yes Yes Yes No Yes Yes
Hospitalization No Yes No No No No
Urine culture result S. malt S. malt E. coli S. malt S. malt Mixed flora
Blood culture result NA Negative NA Negative NA K. pne
Antimicrobial resistance profile† 1 1 NR 2 3 NR
Curative antimicrobial drug treatment Yes Yes Yes Yes Yes Yes
Apyrexia without proper antimicrobial regimen Yes Yes No Yes Yes Yes
Immunosuppressants
 No
 No
 No
 No
 No
 No
*E. coli, Escherichia coli; K. pne, Klebsiella pneumoniae; NA, cultures not requested; NR, not recorded; S. malt, Stenotrophomonas maltophilia.
†The antimicrobial-drug resistance profile is shown for S. maltophilia only. Profiles 1 and 2 had only 1 difference across 17 different antimicrobial drugs (ceftazidime-I vs. -S). Of 14 antimicrobial drugs tested for all 4 S. maltophilia patients, profile 3 had 2 differences from profile 2 and 3 differences from profile 1.

Main Article

Page created: July 15, 2016
Page updated: July 15, 2016
Page reviewed: July 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external